Matridx Bio Closes $32 Million for Pathogen Metagenomics Analyzers

Matridx Biotech of Hangzhou closed a $32 million Series B round to support its pathogen metagenomics devices, which are based on AI and CRISPR-Cas technologies. So far, the company has developed two products: a SARS-CoV-2 nucleic acid detection kit, and a metagenomic next-gen sequencing (mNGS) device that diagnoses over 16,000 DNA pathogens (bacteria, DNA viruses, fungi, parasites) and 200 RNA viruses (HIV, coronaviruses, Dengue viruses etc.). Matridx says its technology offers faster speed, better accuracy and wider detection coverage than the competition. More details.... Share this with colleagues: // //